Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Verapamil

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Verapamil is widely used in the treatment of supraventricular tachyarrhythmias as well as for hypertension and control of symptoms in angina pectoris. Unlike other calcium antagonists, detailed pharmacokinetic data are available for verapamil. Plasma concentrations of verapamil appear to correlate with both electrophysiological and haemodynamic activity after either intravenous or oral drug administration, although considerable intra- and intersubject variation has been found in the intensity of pharmacological effects resulting at specific plasma drug levels.

Verapamil is widely distributed throughout body tissues; animal studies suggest that drug distribution to target organs and tissues is different with parenteral administration from that found after oral administration. The drug is eliminated by hepatic metabolism, with excretion of inactive products in the urine and/or faeces. An N-demethylated metabolite, norverapamil, has been shown to have a fraction of the vasodilator effect of the parent compound in in vitro studies.

After intravenous administration, the systemic clearance of verapamil appears to approach liver blood flow. The high hepatic extraction results in low systemic bioavailability (20%) after oral drug administration. Multicompartmental kinetics are observed after single doses; accumulation occurs during multiple-dose oral administration with an associated decrease in apparent oral clearance. Norverapamil plasma concentrations approximate those of verapamil following single or multiple oral doses of the parent drug.

Because of the complex pharmacokinetics associated with multiple-dose administration and the variation in individual patient responsiveness to the drug, ’standard’ dosing recommendations are difficult to determine; use of verapamil must be titrated to a clinical end-point. Further, the potential for alteration in verapamil’s disposition by the presence of hepatic dysfunction or cardiovascular disorders which result in altered hepatic blood flow is only now becoming apparent. A potentially toxic interaction has been reported between verapamil and digoxin, in which renal excretion of the glycoside is impaired, but the true clinical significance of this remains debatable. Combination therapy with verapamil and β-adrenoceptor blocking compounds has been advocated by some investigators, but may be hazardous because of the additive negative inotropic and chronotropic effects inherent in both agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anavckar, S.N.; Christophidis, N.; Louis, W.J. and Doyle, A.E.: Verapamil in the treatment of hypertension. Journal of Cardiovascular Pharmacology 3: 287–292 (1981).

    Article  Google Scholar 

  • Anderson, P.; Bondesson, U. and Sylven, C: Clinical pharmaco-kinctics of verapamil in patients with atrial fibrillation. European Journal of Clinical Pharmacology 23: 49–57 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Anderson, P.; Bondesson, U; Sylven, C. and Astrom, H.: Plasma concentration response relationship of verapamil in the treatment of angina pectoris. Journal of Cardiovascular Pharmacology 4: 609–614 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Bala Subramanian, V.; Bowles, M.J.; Davies, A.B. and Raftery, E.B.: Combined therapy with verapamil and propranolol in chronic stable angina. American Journal of Cardiology 49: 125–133 (1982).

    Article  Google Scholar 

  • Belz, G.G.; Doering, W.; Munkes, R. and Matthews, J.: Interaction between digoxin and calcium antagonists and antiar-rhythmic drugs. Clinical Pharmacology and Therapeutics 33: 410–417 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Benaim, M.E.: Aystole after verapamil. British Medical Journal 2: 169–170 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Bourne, D.W.A.; Benedek, I.H.; Tan, T.; Dominic, J.A. and McAllister, R.G.: Pharmacokinetics of verapamil following single and multiple intravenous infusions (abstract). American Pharmaceutical Association Academy of Pharmaceutical Sciences 10: 88 (1980).

    Google Scholar 

  • Bowles, M.; Bala Subramanian, V.; Davies, A.B. and Raftery, E.B.: Comparison of the antianginal action of verapamil and propranolol. British Medical Journal 282: 1754 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Braunwald, E.: Mechanism of action of calcium-channel-blocking agents. New England Journal of Medicine. 307: 1618–1627 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Candcll, J.; Valle, V.; Soler, M. and Rius, J.: Acute intoxication with verapamil. Chest 75: 200–201 (1979).

    Article  Google Scholar 

  • Carrasco, H.A.; Fuenmayor, A.; Barboza, J.S. and Gonzalez, G.: Effect of verapamil on normal sinoatriai function and on sick sinus syndrome. American Heart Journal 96: 760–771 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Chew, C.Y.C.; Hecht, H.S.; Collett, J.T.; McAllister, R.G. and Singh, B.N.: Influence of severity of ventricular dysfunction on haemodynamic responses to intravenously administered verapamil in ischemie heart disease. American Journal of Cardiology 47: 917–922 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Cole, S.C.J.; Flanagan, R.J.; Johnston, A. and Holt, D.W.: Rapid high-performance liquid Chromatographie method for the measurement of verapamil and norverapamil in blood, plasma or serum. Journal of Chromatography 218: 621–629 (1981).

    Article  PubMed  CAS  Google Scholar 

  • dcFairc, V. and Lundman, T.: Attempted suicide with verapamil. European Journal of Cardiology 6: 195–198 (1977).

    Google Scholar 

  • Denis, B.; Pellet, J.; Machecourt, J. and Martin-Noel, P.: Verapamil et béta-bloquant une association thérapeutique dangereuse. Nouvelle Presse Médicale 6: 2075 (1977).

    PubMed  CAS  Google Scholar 

  • Dominic, J.A.; Bourne, D.W.A.; Tan, T.G.; Kirsten, E.B. and McAllister, R.G.: The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. Journal of Cardiovascular Pharmacology 3: 25–38 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Dominic, J.A.; McAllister, R.G.; Kuo, C.S.; Reddy, C.P. and Surawicz, B.: Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clinical Pharmacology and Therapeutics 26: 710–714 (1979).

    PubMed  CAS  Google Scholar 

  • Eichclbaum, M.; Albrecht, M.; Kliems, G.; Schafer, K. and Somogyi, A.: Influence of meso-caval shunt or surgery on verapamil kinetics, bioavailability and response. British Journal of Clinical Pharmacology 10: 527–529 (1980a).

    Article  Google Scholar 

  • Eichelbaum, M.; Birket, P.; Grube, E.; Gutgemann, U. and Somogyi, A.: Effects of verapamil on P-R intervals in relation to vcrapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klinische Wochenschrift 58: 919–925 (1980b).

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum, M.; Ende, M.; Remberg, G.; Schomerus, M. and Dengler, HJ.: The metabolism of 14C-D,L-verapamil in man. Drug Metabolism and Disposition 7: 145–148 (1979).

    PubMed  CAS  Google Scholar 

  • Eichelbaum, M.; Somogyi, A.; von Unruh, G.E. and Dengler, H.J.: Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. European Journal of Clinical Pharmacology 19: 133–137 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Ellrodt, G.; Chew, C.Y.C. and Singh, B.N.: Therapeutic implications of slow-channel blockade in cardiocirculatory disorders. Circulation 62: 669–679 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Fleckenstein, A.: Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annual Review of Pharmacology and Toxicology 17: 149–166 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Follath, F.; Schutz, E. and Buhler, F.: Serum drug levels on slow release verapamil. Clinical Pharmacology and Therapeutics 33: 205 (1983).

    Google Scholar 

  • Freedman, S.B.; Richmond, D.R.; Ashley, J.J. and Kelly, D.T.: Vcrapamil kinetics in normal subjects and patients with coronary artery spasm. Clinical Pharmacology and Therapeutics 30: 644–652 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Frishman, W.; Kirsten, E.; Klein, M.; Pine, M.; Johnson, S.M.; Hillis, L.D.; Packer, M.; and Kates, R.: Clinical relevance of vcrapamil plasma levels in stable angina pectoris. American Journal of Cardiology 50: 1180–1184 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Gould, B.A.; Mann, S.; Kieso, H.; Bala Subramanian, V. and Raftery, E.B.: The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65: 22–27 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Hamann, S.R.; Rideout, L.J.; Todd, G.D. and McAllister, R.G.: Results of combined administration of propranolol and verapamil in anesthetized dogs (abstract). Pharmacologist 24: 228 (1982).

    Google Scholar 

  • Hamann, S.R.; Todd, G.D. and McAllister, R.G.: The pharmacology of verapamil, V. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology 27: 1–8 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Harapat, S.R. and Kates, R.E.: High performance liquid Chromatographie analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. Journal of Chromatography 181: 484–489 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Hege, H.G.: Gas Chromatographie determination of verapamil in plasma and urine. Arzneimittel-Forschung 29: 1681–1684 (1979).

    PubMed  CAS  Google Scholar 

  • Hordof, A.J.; Edie, R.; Malm, J.R.; Hoffman, B.F. and Rosen, M.R.: Electrophysiologic properties and response to pharmacologie agents of fibers from diseased human atria. Circulation 54: 774–779 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Imanishi, S.; McAllister, R.G. and Surawicz, B.: The effects of vcrapamil and lidocaine on the automatic depolarizations in guinea-pig ventricular myocardium. Journal of Pharmacology and Experimental Therapeutics 207: 294–303 (1978).

    PubMed  CAS  Google Scholar 

  • Jaouni, T.M.; Leon, M.B.; Rosing, D.R. and Fales, H.M.: Analysis of verapamil in plasma by liquid chromatography. Journal of Chromatography 182: 473–477 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Johnston, A.; Burgess CD. and Hamer, J.: Systemic availability of oral vcrapamil and effect on PR interval in man. British Journal of Clinical Pharmacology 12: 397–400 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Kates, R.E.; Keefe, D.L.D.; Schwartz, J.; Harapat, S.; Kirsten, E.B. and Harrison, D.C.: Verapamil disposition kinetics in chronic atrial fibrillation. Clinical Pharmacology and Therapeutics 30: 44–51 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Keefe, D.L. and Kates, R.E.: Myocardial disposition and cardiac pharmacodynamics of verapamil in the dog. Journal of Pharmacology and Experimental Therapeutics 220: 91–96 (1982).

    PubMed  CAS  Google Scholar 

  • Kecfe, D.L; Yee, Y.G. and Kates, R.E.: Verapamil protein binding in patients and in normal subjects. Clinical Pharmacology and Therapeutics 29: 21–26 (1981).

    Article  Google Scholar 

  • Klein, H.O.; Lang, R.; De Segni, E. and Kaplinsky, E.: Verapamildigoxin interaction. New England Journal of Medicine 303: 160 (1980).

    PubMed  CAS  Google Scholar 

  • Klein, H.O.; Lang, R.; Weiss, E.; DeSegni, E.; Libhaber, C; Fuerrero, J. and Kaplinsky, E.: The influence of verapamil on serum digoxin concentrations. Circulation 65: 998–1003 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Koike, Y.; Shimamura, K.; Shudo, J. and Saito, H.: Pharmaco-kinetics of verapamil in man. Research Communications in Chemical Pathology and Pharmacology 24: 37–47 (1979).

    PubMed  CAS  Google Scholar 

  • Kriklcr, D.M. and Spurrel, R.A.J.: Verapamil in the treatment of paroxysmal supraventricular tachycardias. Postgraduate Medicine 50: 447–453 (1974).

    Article  Google Scholar 

  • Leon, M.B.; Rosing, D.R.; Bonow, R.O.; Lipson, L.C. and Epstein, S.E.: Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. American Journal of Cardiology 48: 131–137 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Leonard, R.G. and Tolbert, R.L.: Calcium channel blocking agents. Clinical Pharmacy 1: 17–23 (1982).

    PubMed  CAS  Google Scholar 

  • Lewis, G.R.J.; Morley, K.D.; Lewis, B.M. and Bones, P.J.: The treatment of hypertension with verapamil. New Zealand Medical Journal 87: 351–354 (1978).

    PubMed  CAS  Google Scholar 

  • Lim, C.K.; Rideout, J.M. and Sheldon, J.W.S.: Determination of verapamil and norverapamil in serum by high-performance liquid chromatography. Journal of Liquid Chromatography 6: 887–893 (1983).

    Article  CAS  Google Scholar 

  • Mangiardi, L.M.; Hariman, R.; McAllister, R.G.; Bhargava, V.; Surawicz, B. and Shabetai, R.: Hemodynamic and electro-physiologic effects of verapamil: Correlations with drug plasma levels. Circulation 57: 336–372 (1978).

    Article  Google Scholar 

  • McAllister, R.G.: Clinical pharmacology of slow channel blocking agents. Progress in Cardiovascular Diseases 25: 83–102 (1982).

    Article  PubMed  CAS  Google Scholar 

  • McAllister, R.G.; Bourne, D.W.A. and Dittert, L.W.: The pharmacology of verapamil, I. Elimination kinetics in dogs and correlation of plasma levels with effects on the electrocardiogram. Journal of Pharmacology and Experimental Therapeutics 202: 38–44 (1977).

    PubMed  CAS  Google Scholar 

  • McAllister, R.G. and Howell, S.M.: Fluorometric assay of verapamil in biological fluids and tissues. Journal of Pharmaceutical Sciences 65: 431–432 (1976).

    Article  PubMed  CAS  Google Scholar 

  • McAllister, R.G. and Kirslen, E.B.: The pharmacology of vera-pamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clinical Pharmacology and Therapeutics 31: 418–426 (1982).

    Article  PubMed  CAS  Google Scholar 

  • McAllister, R.G.; Tan, T.G. and Bourne, D.W.A.: GLC assay of verapamil in plasma: Identification of fluorescent metabolites after oral drug administration. Journal of Pharmaceutical Sciences 68: 547–577 (1979).

    Article  Google Scholar 

  • McGowan, F.X.; Reiter, M.J.; Pritchett, E.L.C. and Shand, D.G.: Verapamil plasma binding: Relationship to α-1-acid glyco-protein and drug efficacy. Clinical Pharmacology and Therapeutics 33: 485–490 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Mcllheny, H.M.: Metabolism of (14C) verapamil. Journal of Medicinal Chemistry 14: 1178–1184 (1971).

    Article  Google Scholar 

  • Mcrlens, H.M.; Mannebach, H. and Gleichmann, U.: 24 Stundiger electrischer Herstillstand nach intravenöser Gabe von 10 mg Verapamil. Zeitschrift für Kardiologie 69: 414–416 (1980).

    Google Scholar 

  • Naylcr, W.G.; McInnes, I.; Swann, J.B.; Price, J.M.; Race, D. and Lowe, T.E.: Some effects of iproveratril (Isoptin) on the cardiovascular system. Pharmacology and Experimental Therapeutics 161: 247 (1968).

    Google Scholar 

  • Nelson, K.; Woodcock, B.G. and Kirslen, R.: Improvement of the quantitative determination of verapamil in human plasma. International Journal of Clinical Pharmacology and Biophar-macy 17: 375–379 (1979).

    CAS  Google Scholar 

  • Ncugebaucr, G.: Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetized dog. Cardiovascular Research 12: 247–254 (1978).

    Article  Google Scholar 

  • Packer, M.; Meller, J.; Medina, N.; Yushak, M; Smith, H.; Holt, J.; Ciuerrcro, J.; Todd, G.D.; McAllister, R.G. and Gorlin, R.: Hcmodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 65: 660–668 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Pedcrscn, K.E.; Christiansen, B.D.; Kjaer, K..; Klitgaard, N.A. and Nielsen-Judsk, N.: Verapamil-induced changes in digoxin ki-ncucs and intraerythrocytic sodium concentration. Clinical Pharmacology and Therapeutics 34: 8–13 (1983).

    Article  Google Scholar 

  • Pedcrson, K.E.; Dorph-Pedersen, A.; Hvidt, S.; Klitgaard, N.A. and Nielscn-Kudsk, F.: Digoxin-verapamil interaction. Clinical Pharmacology and Therapeutics 30: 311–316 (1981).

    Article  Google Scholar 

  • Roddy, C.P.; McAllister, R.G.; Slack, J.D.; Frazier, P. and Todd, G.D.: Absence of specific electrocardiographic: end points as indicators of drug effect during chronic oral verapamil therapy (abstract). Circulation 64 (Suppl. IV): 138 (1981).

    Google Scholar 

  • Reiter, M.J.; Shand, D.G.; Aaronsen, L.M.; Wagoner, R.; McCarthy, E. and Pritchett, E.L.C: Pharmacokinetics of verapamil: Experience with a sustained intravenous infusion regimen. American Journal of Cardiology 50: 716–721 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Rosen, M.R.; Ilvento, J.P.; Gelband, H. and Merker, C: Effects of verapamil on electrophysiologic properties of canine cardiac Purkinje fibers. Journal of Pharmacology and Experimental Therapeutics 189: 294–303 (1974).

    Google Scholar 

  • Sakurai, M.; Yasuda, Y.; Kato, N.; Nomura, A.; Fukita, M.; Nish-ino, T.; Koike, Y. and Saito, H.: Acute and chronic effects of verapamil in patients with paroxysmal supraventricular tachycardia. American Heart Journal 105: 619–628 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Schols, M.; Mooy, J.; van Hooff, M.; van Baak, M.A. and Rahn, K.H.: Studies on the disposition of verapamil in patients with renal failure. Naunyn-Schmiedeberg’s Archives of Pharmacology 322 (Supplement): R130 (1983).

  • Sehomerus, M.; Spiegelhalder, B.; Stieren, B. and Eichelbaum, M.: Physiologic disposition of verapamil in man. Cardiovascular Research 10: 605–612 (1976).

    Article  Google Scholar 

  • Schwartz, JB.; Keefe, D.; Kates, R.E.; Kirsten, E. and Harrison, D.C.: Acute and chronic pharmacodynamic int, action of verapamil and digoxin in atrial fibrillation. Circulation 65: 1163–1170 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Scabra-Gomes, R.; Rickards, A. and Sutton, R.: Hemodynamic effects of verapamil and practolol in man. European Journal of Cardiology 4: 79–85 (1976).

    Google Scholar 

  • Scmplicini, A.; Pessina, A.C.; Rossi, G.P.; Padrini, R.; Tagliafierro, R.; Quintarelli, G.F.; Ferrari, M. and Dal Palu, C: Plasma levels of verapamil and its effects on blood pressure, body fluid volumes and renal function in hypertensive patients. International Journal of Clinical Pharmacy Research 11: 81–86 (1982).

    Google Scholar 

  • Shand, D.G.; Hammill, S.C.; Aaronsen, L. and Pritchett, E.L.C: Reduced verapamil clearance during long-tern oral administration. Clinical Pharmacology and Therapeutics 30: 701–703 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Singh, B.N.; Collett, J.T. and Chew, C.Y.C.: New perspectives in the pharmacologie therapy of cardiac arrythmias. Progress in Cardiovascular Disease 42: 243–301 (1980).

    Article  Google Scholar 

  • Singh, B.N.; Ellrodt, G. and Peter, C.T.: Verapamil: A review of its pharmacologie properties and therapeutic use. Drugs 15: 169–197 (1978).

    Article  PubMed  Google Scholar 

  • Somogyi, A.; Albrecht, M.; Kliems, G.; Schäfer, K. and Eichelbaum, M.: Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. British Journal of Clinical Pharmacology 12: 51–60 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Spiegelhalder, B. and Eichelbaum, M.: Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard. Arzneimittel-Forschung 27: 94–97 (1977).

    PubMed  CAS  Google Scholar 

  • Spivack, C; Ocken, S. and Frishman, W.H.: Calcium Antagonists. Clinical use in the treatment of systemic hypertension. Drugs 25: 154–177 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Storstcin, L.; Midtbo, K.; Hals, O. and Myhre, E.: Antihypertensivc effect of verapamil in relation to plasma concentrations of verapamil and its active metabolite norverapamil. Current Therapeutic Research 29: 112–119 (1981).

    Google Scholar 

  • Sung, R.J.; Elscr, B. and McAllister, R.G.: Intravenous verapamil for termination of re-entrant supraventricular tachycardias: Imracardiac studies correlated with plasma verapamil concentrations. Annals of Internal Medicine 93: 682–689 (1980).

    PubMed  CAS  Google Scholar 

  • Tartaglione, T.A.; Pieper, J.A.; Lopez, L.L. and Mehta, J.: Phar-macokinetics of verapamil and norverapamil during long-term oral therapy. Research Communications in Chemical Pathology and Pharmacology 40: 15–27 (1983).

    PubMed  CAS  Google Scholar 

  • Todd, G.D.; Bourne, D.W.A. and McAllister, R.G.: Measurement of verapamil concentrations in plasma by gas chromatography and high pressure liquid chromatography. Therapeutic Drug Monitoring 2: 411–416 (1980).

    PubMed  CAS  Google Scholar 

  • Urthaler, F. and James, T.N.: Experimental studies in the patho-genesis of asystole after verapamil in the dog. American Journal of Cardiology 44: 651–656 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Vasiliades, J.; Wilkerson, K.; Ellul, D.; Anticoli, M. and Rocchini, P.: Gas-chromatographic determination of verapamil and norverapamil, with a nitrogen-selective detector. Clinical Chemistry 28: 638–641 (1982).

    PubMed  CAS  Google Scholar 

  • Wagner, J.G.; Rocchini, A.P. and Vasiliades, J.: Prediction of steady-state verapamil plasma concentrations in children and adults. Clinical Pharmacology and Therapeutics 32: 172–181 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Woodcock, B.G.; Hopf, R. and Kaltenbach, M.: Verapamil and norverapamil plasma concentrations during long-term therapy in patients with hypertrophie obstructive cardiomyopathy. Journal of Cardiovascular Pharmacology 2: 17–23 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Woodcock, B.G.; Rietbrock, I.; Vohringer, H.F. and Rietbrock, N.: Verapamil disposition in liver disease and intensive-care patients: Kinetics, clearance, and apparent blood flow relationships. Clinical Pharmacology and Therapeutics 29: 27–34 (1981a).

    Article  PubMed  CAS  Google Scholar 

  • Woodcock, B.G.; Schulz, W.; Kober, G. and Rietbrock, N.: Direct determination of hepatic extraction of verapamil in cardiac patients. Clinical Pharmacology and Therapeutics 30: 52–56 (1981b).

    Article  PubMed  CAS  Google Scholar 

  • Yong, C.L.; Kunka, R.L. and Bates, T.R.: Factors affecting the plasma protein binding of verapamil and norverapamil in man. Research Communications in Chemical Pathology and Pharmacology 30: 329–339 (1980).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Service, Veterans Administration Medical Center, Lexington, Kentucky, 40511, USA

    Scott R. Hamann, Robert A. Blouin &  R. G. McAllister Jr (Associate Chief of Staff/R&D(151)

  2. The Graduate Center for Toxicology, The College of Pharmacy, Lexington, USA

    Scott R. Hamann, Robert A. Blouin &  R. G. McAllister Jr (Associate Chief of Staff/R&D(151)

  3. The Departments of Medicine and Pharmacology, University of Kentucky College of Medicine, Lexington, USA

    Scott R. Hamann, Robert A. Blouin &  R. G. McAllister Jr (Associate Chief of Staff/R&D(151)

Authors
  1. Scott R. Hamann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Blouin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. G. McAllister Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamann, S.R., Blouin, R.A. & McAllister, R.G. Clinical Pharmacokinetics of Verapamil. Clin Pharmacokinet 9, 26–41 (1984). https://doi.org/10.2165/00003088-198409010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198409010-00002

Keywords

Search

Navigation